. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Cladribine/administration & dosageCladribine/adverse effectsCladribine/therapeutic useClinical Trials, Phase III as TopicDisease ProgressionDose-Response Relationship, DrugHumansImmunosuppressive Agents/administration & dosageImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useMultiple Sclerosis, Relapsing-Remitting/drug therapyMultiple Sclerosis, Relapsing-Remitting/physiopathologyTreatment Outcome
Substances: See more » Immunosuppressive AgentsCladribine
Year: 2009 PMID: 19527090 DOI: 10.1586/erp.09.25
Source DB: PubMed Journal: Expert Rev Pharmacoecon Outcomes Res ISSN: 1473-7167 Impact factor: 2.217